Co-amoxiclav reduces infection after gastrostomy

Percutaneous endoscopic gastrostomy is commonly used to ensure enteral nutrition in patients with dysphagia. Results of previous controlled studies of antibiotic prophylaxis in preventing infection, the main complication, have been conflicting. Preclik et al (p 881) conducted a prospective, randomised, double blind, placebo controlled study to determine whether intravenous co-amoxiclav before percutaneous endoscopic gastrostomy reduces infectious complications among adults with dysphagia due to cancer or neurological disease. The rate of infection 7 days after the procedure was significantly reduced in the antibiotic group (20% v 65%). The rate of wound infection requiring antibiotics or surgery was 2% in the co-amoxiclav group and 26% in the placebo group.